TransCode Therapeutics up as brain cancer drug shows promise in animal study

Transcode Therapeutics

07/06/2023 09:57

** TransCode Therapeutics Inc's shares  RNAZ.O  rise 20.2%
to $3.86 - among top gainers across U.S. stock exchanges 
premarket
    ** Drug developer says animal study of its lead drug
candidate to treat a type of brain tumor supported further
development 
    ** The study showed the drug inhibited growth and resulted
in death of human brain tumor cells implanted in animals  
     ** Glioblastoma multiforme is the most common and
aggressive form of brain tumors, co says
    ** Up to Tuesday's close, stock had fallen ~76% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))